Goldzieher J W, de la Peña A, Chenault C B, Cervantes A
Am J Obstet Gynecol. 1975 Jul 1;122(5):625-36. doi: 10.1016/0002-9378(75)90062-9.
Twenty-one-day treatment cycles of ethynylestradiol or mestranol at dosages of 50 to 100 mug per day were administered to 191 normal volunteer women from six cycles, followed by six cycles of this estrogen treatment combined with 2.5 mg. of norethindrone acetate, 2 mg. of megestrol acetate, or 0.5 mg. of norgestrel. The drugs were prepared to insure uniform bioavailabiltiy. Plasma FSH and LH were determined by radioimmunoasay during the last week of medication intake in each cycle. In another study, a large number of blood samples were obtained at various times during the menstrual cycle from women using IUD's (as a control population) and from women who had been taking oral contraceptives regularly for 5 to 12 years. With the various estrogen treatments, the median FSH level showed no change at any estrogen dose at the end of the first cycle. From the second cycle on, a stable, dose-related fall was obtained with the 80 or 100 mug per day doses. The addition of any of the three progestins caused a prompt, stable, further fall in FSH level. By contrast, the median LH level rose in the first cycle with all estrogen regimens, and then fell progressively in a dose-related fashion in cycles 2 to 6. The addition of a progestational agent also caused a further prompt and stable fall in LH during cycles 7 to 12. Except for a minimal indication of greater LH suppression by ethynylestradiol as compared to mestranol at 50 mug per day, all other indices and dosages showed ethynylestradiol and mestranol to be essentially equipoten under these experimental conditions. Long-term administration of oral contraceptives produced a comparable degree of gonadotropin suppression. There was a suggestion of slightly less FSH suppression with agents using 50 to 75 mug per day of estrogen than from those with 100 mug per day. Both in normal controls (IUD cycles) and in cycles under chronic treatment with oral contraceptives, pulses of both FSH and LH were seen with some frequency, at times distant from the "periovulatory" period. The significance and origin of these random FSH and LH pulses is unknown.
对191名正常志愿者女性进行了为期21天的治疗周期,每天给予50至100微克剂量的乙炔雌二醇或炔雌醇甲醚,共六个周期,随后是六个周期的这种雌激素治疗,并联合2.5毫克醋酸炔诺酮、2毫克醋酸甲地孕酮或0.5毫克炔诺孕酮。制备药物以确保生物利用度一致。在每个周期药物摄入的最后一周,通过放射免疫测定法测定血浆促卵泡激素(FSH)和促黄体生成素(LH)。在另一项研究中,在月经周期的不同时间从使用宫内节育器的女性(作为对照人群)和定期服用口服避孕药5至12年的女性中采集了大量血样。在各种雌激素治疗中,在第一个周期结束时,任何雌激素剂量下的FSH中位数水平均无变化。从第二个周期开始,每天80或100微克剂量可导致稳定的、与剂量相关的下降。添加三种孕激素中的任何一种都会导致FSH水平迅速、稳定地进一步下降。相比之下,在第一个周期中,所有雌激素方案下的LH中位数水平均升高,然后在第2至6个周期中以与剂量相关的方式逐渐下降。添加孕激素制剂在第7至12个周期中也会导致LH迅速、稳定地进一步下降。除了在每天50微克剂量下,与炔雌醇甲醚相比,乙炔雌二醇对LH的抑制作用略有增强外,在这些实验条件下,所有其他指标和剂量均显示乙炔雌二醇和炔雌醇甲醚基本等效。长期服用口服避孕药产生了相当程度的促性腺激素抑制作用。有迹象表明,每天使用50至75微克雌激素的制剂对FSH的抑制作用略低于每天使用100微克雌激素的制剂。在正常对照组(宫内节育器周期)和口服避孕药长期治疗的周期中,FSH和LH都会出现一些频率的脉冲,有时与“排卵期”相隔较远。这些随机的FSH和LH脉冲的意义和来源尚不清楚。